Status: Recruiting
Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:
Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS
Participants needed: 116
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: Centre Francois BaclesseUpdated: Oct 7, 2025Locations: 4
Eligibility criteria
Patient ≥ 18 years old [+6]
Patient with an active implantable medical device or any other implanted electro... [+13]